Mikita, J. Stephen
Mitchel, Jules
Gatto, Nicolle M.
Laschinger, John
Tcheng, James E.
Zeitler, Emily P.
Swern, Arlene S.
Flick, E. Dawn
Dowd, Christopher
Lystig, Theodore
Calvert, Sara B. http://orcid.org/0000-0003-4229-2729
Funding for this research was provided by:
U.S. Food and Drug Administration (R18FD005292)
Article History
Received: 24 December 2019
Accepted: 9 June 2020
First Online: 22 June 2020
Compliance with Ethical Standards
:
: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Arlene Swern is an employee and stockholder for Celgene Corp. E. Dawn Flick is a current employee of Celgene Corp., and a past employee of Genentech, Inc. Nicolle Gatto was an employee and shareholder of Pfizer at the time of manuscript submission, she is a current employee of Aetion, Inc. John Laschinger was at the U.S. FDA at the time of the project, he is a current employee of W. L. Gore & Associates. Emily Zeitler was at the Duke Clinical Research institute at the time of the project, she is a current employee of the Geisel School of Medicine at Dartmouth College.